Vivimed Labs reports consolidated net loss of Rs 22.03 crore in the September 2022 quarter

Dynacons Systems & Solutions Ltd, Selan Explorations Technology Ltd, Pitti Engineering Ltd and Fertilizers & Chemicals Travancore Ltd are among the other losers in the BSE’s ‘B’ group today, 20 June 2022.

Vivimed Labs Ltd leads losers in ‘B’ group

More than 100 stocks, including Wipro, Zomato, Welspun India, Vivimed Labs, Spicejet PNB Housing Finance, Glenmark Pharmaceuticals, touched their 52-week low on the BSE.

Taking Stock | Market falls 1.5% on rate hike worries; more than 100 stocks hit 52-week low

Vivimed Labs fell 6.35% to Rs 14.75 after State Bank of India initiated a forensic audit following the firm’s proposal to restructure its debt.

Vivimed Lab tumbles after SBI intiates forensic audit

Vivimed Labs Consolidated December 2021 Net Sales at Rs 56.52 crore, down 79.66% Y-o-Y

In another transaction Emerging India Growth Fund sold 80,000 shares of Mitcon Construction and Engineering Services at Rs 75.40 per share.

NSE-BSE bulk deals: SBI Cap sold 6 lakh shares of Vivimed Labs

Among other deals, Sunidhi Securities & Finance acquired 10 lakh equity shares of Pricol at Rs 94.05 per share, while Alpha Leon Enterprises LLP purchased 4,22,237 equity shares of Vivimed Labs at Rs 22.65 per share.

Bulk Deals | Equity Intelligence India Buys 1% Stake In Cupid; Plutus Capital Raises Holding In Mohini Health

Vivimed Labs reports consolidated net loss of Rs 27.46 crore in the March 2021 quarter

Ramesh Krishnamurthy, CEO of Vivimed Labs Ltd said,

Vivimed Lab extend gains after first export shipment of famotidine tablets to Canada

Drug firm Vivimed Labs on Monday said it has exported the first shipment of Famotidine tablets that work by decreasing the amount of acid in the stomach, to Canada.The export to Canada is for Famotidine tablets in the strengths of 40mg and 20mg, Vivimed Labs said in a regulatory filing.

Vivimed Labs exports Famotidine tablets to Canada

On Sensex, Vivimed closed at the upper circuit of Rs29.70 per piece higher by 4.95%.

Vivimed Labs make first shipment of Famotidine tablets to Canada; Stock ends at 5% upper circuit

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Vivimed Labs Limited makes active ingredients for a range of home, personal care and industrial products and is engaged in contractual manufacturing for active pharmaceutical ingredient and contract manufacturing of formulations for generic companies

Vivimed Labs Ltd